Our current findings suggest that the JAK‐STAT inhibitor tofacitinib combined with immunotherapy could be a promising strategy as it blocks the immunotherapy‐induced immunoreaction, such as the IFNγ‐induced immunoescape phenotype in NSCLC cells. Here, IFNG is linked to non-small cell lung carcinoma.